patent.fyi
Applications  /  US 2026/0355288
United States Patent Application Publication

US 2026/0355288 A1

Published
Nov 12, 2026
Filed
Sep 27, 2024
Earliest date on the face
Sep 28, 2023
Classification
A61K 38/28
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Glucose dependent receptor stimulation

What ifWhat if the active ingredient were a glucagon-like peptide-1 receptor agonist that stimulates endogenous insulin release?
Claim language“an Insulin”

A peptide agonist binds glucagon-like peptide-1 receptors on pancreatic beta cells. When glucose is elevated, receptor signaling amplifies the release of insulin from secretory granules.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Insulin reference samples for assay training

An analytical training laboratory uses an insulin dispersion in a propylene glycol and water carrier as a reference sample. A matched carrier blank and serial dilutions of the dispersion occupy separate wells of a microplate. Trainees measure the wells with an insulin immunoassay and calculate recovery from the measured and assigned concentrations.

Component substitution

Glycerol as the water miscible carrier

Glycerol replaces propylene glycol in an aqueous insulin formulation. Glycerol is dissolved in the aqueous buffer before the insulin solution is added with gentle mixing. Glycerol increases the viscosity of the continuous phase, and size exclusion chromatography measures the soluble aggregate fraction after storage.

Parameter or scale variation

Three fill volumes for storage testing

A single batch of insulin in a propylene glycol and water carrier is dispensed into identical 2 mL glass vials at fill volumes of 0.25, 0.75, and 1.50 mL. All vials use the same closure and are stored upright at 5 °C. Separate vials from each fill group are sampled on days 0, 7, and 28 to measure insulin concentration and soluble aggregates at each headspace volume.

Combination with existing systems

Cartridge feed for bench flow testing

A glass cartridge containing insulin in an aqueous propylene glycol carrier mounts in a programmable syringe pump. The pump drive advances the cartridge plunger, and the cartridge outlet connects through low protein binding tubing to a fraction collector. The collector captures timed samples for insulin measurement, and the collected mass is divided by the sampling interval to determine the delivered mass flow.

Dialysis cell for measuring insulin release

A semisolid containing insulin, mineral oil, and cetyl alcohol is spread across a defined area of a dialysis membrane in a two chamber diffusion cell. The opposite chamber contains stirred aqueous buffer and a sampling port, and the membrane is prequalified for passage of insulin from a reference solution. Equal volumes of fresh buffer replace the withdrawn samples, and measured insulin concentrations and replacement volumes are used to calculate cumulative mass transfer per unit area.

Automated or data-driven variant

Automated imaging of dispersion uniformity

A camera and diffuse backlight are mounted on opposite sides of a clear vial containing an insulin suspension in a propylene glycol and water carrier. A motorized cradle inverts the vial and returns it upright before the camera records a time series at fixed exposure. Software subtracts an image of a matched carrier blank and tracks the vertical intensity profile and sediment boundary to quantify settling.

Specific version of a part

Buffered aqueous insulin solution

Water for injection serves as the solvent, and sodium phosphate controls pH. Sodium chloride adjusts tonicity for subcutaneous administration.

Protamine and zinc suspension

Protamine and zinc form a crystalline complex with insulin that remains suspended in an aqueous vehicle. After subcutaneous injection, the crystals dissolve gradually and release insulin into the surrounding fluid.

Porous particles for inhalation

Insulin adsorbs onto porous particles that disperse into an inhalable aerosol. The particles dissolve in lung lining fluid and release insulin for absorption.

Polymer microsphere depot

Poly(lactic-co-glycolic acid) microspheres encapsulate insulin and remain at the subcutaneous injection site. Water enters the particles, and insulin exits through pores as the polymer hydrolyzes.

Dissolving microneedle matrix

Dry microneedle tips made from sodium hyaluronate hold the insulin. After insertion into the skin, interstitial fluid dissolves the tips and releases the dose.

Insulin in propylene glycol

Recombinant human insulin is dissolved in an aqueous buffer containing propylene glycol. The buffer controls pH, and propylene glycol contributes to tonicity.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2014/0206611 A1
Published
Jul 24, 2014
Filed
Mar 20, 2014
Class
A61K 38/28
Document BUS 8,946,208 B2
Published
Feb 3, 2015
Filed
Aug 29, 2008
Class
A61K 9/0043
Claim 1
Document A
Document B
1.1an Insulin and a pharmaceutical carrier selected from dimethyl sulfoxide (DMSO), urea, propylene glycol, L-Proline, Adeps Suilus, oleic acid, Choline or their salts, Cholesterol, Tween 80, Span 80, cetylic alcohol, essential oils, vegetable oil, mineral oil or combinations thereof.
Additionally, the aqueous pharmaceutical formulation can comprise one or more excipients selected from a group comprising zinc, m-cresol, glycerol, polysorbate 20 and sodium.
A · US 2014/0206611 A1 · ¶ 109
A preferred vehicle comprises from about 60 to about 85 or 80% by volume DMSO and from about 15 or 20 to about 40% by volume propylene glycol, for example about 75% to about 85% by volume dimethyl sulfoxide and about 15 to 25% by volume propylene glycol. A preferred drug for including in this vehicle is diazepam, at a concentration of up to about 100 mg/ml, for example up to about 60 mg/ml, e.g. about 50 mg/ml.
B · US 8,946,208 B2 · ¶ 74

An empty cell means only that no passage was reproduced there.

Statements in these documents
A considerable number of patients, in particular those with increased insulin resistance due to obesity, use large doses to control blood glucose.
A · US 2014/0206611 A1 · ¶ 6
This formulation would allow patients to inject the same number of units of insulin glargine at one third the volume of injection.
A · US 2014/0206611 A1 · ¶ 6
However, it is not always feasible to formulate a drug as an aqueous solution, for example if the solubility of the drug in aqueous media is inadequate.
B · US 8,946,208 B2 · ¶ 3
The non-aqueous vehicles described in this application are suitable for producing compositions for the intranasal delivery of a wide range of drug compounds.
B · US 8,946,208 B2 · ¶ 6
Cite aspatent.fyi, US 2026/0355288 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355288/, SHA-256 c09d09bd79e8a1aa2a43cc77656d65257440f81505915cc50d3af412e128f3bc
First published
Permanent addresshttps://patent.fyi/US20260355288/
Content fingerprint (SHA-256)c09d09bd79e8a1aa2a43cc77656d65257440f81505915cc50d3af412e128f3bc
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi